Claimed effect · Ziconotide

Does Ziconotide help with absence of tolerance and dependence?

B
Grade B — probable, not settledPhase 3 programme; label · effect size: moderate
Short answerProbable, not settled. Human data exist (Phase 3 programme; label) and mostly agree, showing a moderate effect — but too few, too small, or not yet peer-reviewed for a firm answer. Ziconotide does not act on opioid receptors, so there is no tolerance, no dose escalation of the kind opioids require, and no withdrawal syndrome. The trial's maintenance phase showed no loss of effect. This is the central clinical argument for a drug that is otherwise very hard to use.

What the studies show

Ziconotide does not act on opioid receptors, so there is no tolerance, no dose escalation of the kind opioids require, and no withdrawal syndrome. The trial's maintenance phase showed no loss of effect. This is the central clinical argument for a drug that is otherwise very hard to use.

Human trials exist and mostly agree, but there are too few of them, they are too small, or one big one is still reading out. Expect the grade to move.

  1. 1
    Staats PS, Yearwood T, Charapata SG, et al. Intrathecal ziconotide in the treatment of refractory pain in patients with cancer or AIDS: a randomized controlled trial.JAMA, 2004;291:63–70111 randomised. See the duplicate-publication notice below before citing this trial's size or novelty.
  2. 2
    Prialt (ziconotide) intrathecal infusion prescribing information.DailyMed, read 29 Oct 2026Boxed warning, contraindication in pre-existing psychosis, intrathecal route, CSF terminal half-life about 4.6 hours, and the 25-amino-acid structure with three disulfide bonds.

In context

Ziconotide is a synthetic copy of a 25-amino-acid peptide from the venom of the cone snail Conus magus, approved as Prialt in 2004 for severe chronic pain in people who need intrathecal therapy. It blocks N-type calcium channels in the spinal cord — a mechanism unrelated to opioids, with no tolerance and no dependence. In its cancer and AIDS pain trial, pain scores improved 53.1% against 18.1% on placebo. It carries a boxed warning for severe psychiatric and neurological effects.

Ziconotide is approved (rx). Legal status differs by country — see the regulation section or the jurisdiction pages.

Questions

Is Ziconotide proven to help with absence of tolerance and dependence?
Not yet settled. Phase 3 programme; label — LYO grades it B, meaning probable but liable to change as trials read out.
What studies are behind the grade?
Ziconotide does not act on opioid receptors, so there is no tolerance, no dose escalation of the kind opioids require, and no withdrawal syndrome. The trial's maintenance phase showed no loss of effect. This is the central clinical argument for a drug that is otherwise very hard to use.
Is Ziconotide approved for this?
Ziconotide is an approved medicine (Approved (Rx)); whether this particular outcome is a licensed indication is stated on the compound page's regulation section.

Other outcomes for Ziconotide

Written and maintained by LYO Research — how pages are written and checked. Reviewed 29 October 2026. Grades count human evidence only; see how LYO grades. Not medical advice. Correct this page →